iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology.
Share this article
PLYMOUTH MEETING, Pa., Jan. 13, 2021 /PRNewswire/ New research in the January 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers. The study comes from the University of Alberta, Faculty of Medicine and Dentistry in Alberta, Canada, with findings based on self-reported results from the Canadian Community Health Survey (CCHS) from 2007-2016. According to the author, the results also point to evidence of screening disparities being linked to lower socioeconomic status and identifiable minority race echoing a similar study conducted in the United States by the Centers for Disease Control.
Published: Jan 08, 2021
SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ Nearly all cancer patients face fear, anxiety, and uncertainty following diagnosis and treatment. Cancer-related distress can impact a patient s emotional and physical well-being, which for many has been further compounded by the COVID-19 pandemic. Founded by a team of biotech veterans, Blue Note Therapeutics, Inc., is leveraging deep scientific and clinical expertise, neuroscience, and digital innovation to make mental health care available to any cancer patient at any time. In 2020, the company launched
COVID Cancer Care, a digital program intended to help adults with cancer cope with stress and anxiety related to the COVID-19 pandemic.
Share this article
Share this article
MADISON, Wis., Jan. 12, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in
Cancer Prevention Research, a Journal of the American Association for Cancer Research, that expands on foundational clinical study findings to include a key younger population. Study results show that among average-risk adults between the ages of 45 and 49 Cologuard® (mt-sDNA) demonstrated test specificity of 95.2% in participants with non-advanced precancerous lesions or negative findings at colonoscopy and 96.3% in only those with negative colonoscopy findings. These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.